[go: up one dir, main page]

EP1305300A1 - Nouveaux beta-mimetiques a action lente, leurs procedes de production et leur utilisation comme medicament - Google Patents

Nouveaux beta-mimetiques a action lente, leurs procedes de production et leur utilisation comme medicament

Info

Publication number
EP1305300A1
EP1305300A1 EP01929560A EP01929560A EP1305300A1 EP 1305300 A1 EP1305300 A1 EP 1305300A1 EP 01929560 A EP01929560 A EP 01929560A EP 01929560 A EP01929560 A EP 01929560A EP 1305300 A1 EP1305300 A1 EP 1305300A1
Authority
EP
European Patent Office
Prior art keywords
compounds
nitrogen
general formula
group
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01929560A
Other languages
German (de)
English (en)
Inventor
Kurt Schromm
Alexander Walland
Karl-Heinz Bozung
Hermann Schollenberger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ECSP003424 external-priority patent/ECSP003424A/es
Priority claimed from DE2000151318 external-priority patent/DE10051318A1/de
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Publication of EP1305300A1 publication Critical patent/EP1305300A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • H—ELECTRICITY
    • H03—ELECTRONIC CIRCUITRY
    • H03F—AMPLIFIERS
    • H03F2200/00—Indexing scheme relating to amplifiers
    • H03F2200/331—Sigma delta modulation being used in an amplifying circuit

Definitions

  • the present invention relates to new betamimetics of the general formula
  • radicals R ⁇ and R2 can have the meanings given in the claims and in the description, processes for their preparation and their use as medicaments.
  • Betamimetics ( ⁇ -adrenergic substances) are known from the prior art. They can be used in a variety of therapeutic areas.
  • betamimetics which are characterized by a longer duration of action and can therefore be used for the production of medicaments with a longer activity.
  • the present invention relates to compounds of the general
  • R3 benzyl which may optionally be substituted by methoxy;
  • R 4 is hydrogen or
  • R3 and R 4 together form a -CO-CH2-O- bridge, the carbonyl group of this bridge being bound to the nitrogen,
  • Preferred compounds of general formula 1 are those in which
  • R1 a remainder selected from
  • R5 dimethylamino, methoxy or butoxy
  • X is a nitrogen or a carbon
  • R 6 if X is nitrogen methoxyphenyl or if X is carbon is a fused phenyl ring which is also linked to X.
  • R3 BBeennzzyyll that c can optionally be substituted by methoxy
  • R4 is hydrogen
  • X is nitrogen or carbon
  • R 6 if X is nitrogen methoxyphenyl or if X is carbon is a fused phenyl ring which is also linked to X.
  • the invention relates to the respective compounds of the formula optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates and in the form of the free bases or the corresponding acid addition salts with pharmacologically acceptable acids such as, for example, acid addition salts with hydrohalic acids - for example hydrochloric or hydrobromic acid - or organic acids - such as Acetic, oxalic, fumaric, diglycolic acid or methanesulfonic acid.
  • pharmacologically acceptable acids such as, for example, acid addition salts with hydrohalic acids - for example hydrochloric or hydrobromic acid - or organic acids - such as Acetic, oxalic, fumaric, diglycolic acid or methanesulfonic acid.
  • the salts of hydrochloric acid, methanesulfonic acid and acetic acid are particularly preferred according to the invention.
  • Example 3 1 -r3- (4-methoxybenzylamino) -4-hydroxyphenyl-2- [4- (1 -benzimidazoIvD- 2-methyl-2-butylamino1ethanol:
  • the compounds of general formula 1 are distinguished by a wide range of possible uses in the therapeutic field. Emphasis should be given to those uses for which the compounds of the formula according to the invention can preferably be used as beta-mimetics due to their pharmaceutical activity. These include, for example, the therapy of bronchial asthma (sagging of the bronchial muscle), the treatment of the inflammatory component in COPD, the inhibition of premature contractions in obstetrics (tocolysis), the restoration of the sinus rhythm in the heart in the case of atrio-ventricular block and the elimination of bradycal cardiac arrhythmias (Antiarrhythmic), therapy of circulatory shock (vasodilation and increase in cardiac output) as well as the treatment of itching and inflammation of the skin.
  • bronchial asthma sagging of the bronchial muscle
  • the treatment of the inflammatory component in COPD the inhibition of premature contractions in obstetrics (tocolysis)
  • the restoration of the sinus rhythm in the heart in the case of atrio-ventricular block and the elimination of
  • the compounds of the general formula _ can be used alone or in combination with other active compounds of the formula according to the invention. If appropriate, the compounds of the general formula ⁇ can also be used in combination with other pharmacologically active compounds. These are in particular anticholinergics, possibly other betamimetics, antiallergics, PAF antagonists, leukotriene antagonists and steroids, and combinations of active substances thereof.
  • anticholinergics examples include ipratropium bromide, oxitropium bromide and, in particular, tiotropium bromide.
  • Pharmaceutical combinations which contain the tiotropium bromide as a further active ingredient in addition to the compounds of the formula 1 according to the invention are particularly preferred according to the invention. This combination is particularly important in the treatment of asthma or COPD, especially COPD.
  • Suitable forms of application for applying the compounds of the formula 1 are, for example, tablets, capsules, suppositories, solutions, etc.
  • the proportion of the pharmaceutically active compound (s) should in each case be in the range from 0.05 to 90% by weight, preferably 0.1 to 50 % By weight of the total composition.
  • Corresponding tablets can be mixed, for example, by mixing the active ingredient (s) with known auxiliaries, for example inert diluents, such as calcium carbonate, calcium phosphate or milk sugar, and disintegrants
  • the tablets can also consist of several layers.
  • coated tablets can be produced by coating cores produced analogously to the tablets with agents commonly used in tablet coatings, for example collidone or shellac, gum arabic, talc, titanium dioxide or sugar.
  • the core can also consist of several layers.
  • the coated tablet shell can also consist of several layers in order to achieve a depot effect, it being possible to use the auxiliaries mentioned above for the tablets.
  • Juices of the active substances or combinations of active substances according to the invention can additionally contain a sweetener, such as saccharin, cyclamate, glycerol or sugar, and a taste-improving agent, for example flavorings, such as vanillin or orange extract. They can also contain suspending aids or thickeners, such as sodium carboxymethyl cellulose, wetting agents, for example condensation products of fatty alcohols with ethylene oxide, or protective agents, such as p-hydroxybenzoates.
  • Solutions are used in the usual way, e.g. with the addition of isotonants, preservatives, such as p-hydroxybenzoates, or stabilizers, such as alkali metal salts of ethylenediaminetetraacetic acid, if appropriate using emulsifiers and / or dispersants, where, for example, when using water as a diluent, organic solvents can optionally be used as solubilizers or auxiliary solvents , manufactured and filled into injection bottles or ampoules or infusion bottles.
  • the capsules containing one or more active ingredients or combinations of active ingredients can be produced, for example, by mixing the active ingredients with inert carriers, such as lactose or sorbitol, and encapsulating them in gelatin capsules.
  • Suitable suppositories can be produced, for example, by mixing them with carriers, such as neutral fats or polyethylene glycol or its derivatives.
  • auxiliary substances include water, pharmaceutically acceptable organic solvents such as paraffins (e.g. petroleum fractions), oils of vegetable origin (e.g. peanut or sesame oil), monofunctional or polyfunctional alcohols (e.g. ethanol or glycerin), carriers such as e.g. natural stone flours (e.g. kaolins, clays, talc, chalk) synthetic stone flours (e.g. highly disperse silicic acid and silicates), sugar (e.g. cane, milk and dextrose) emulsifiers (e.g. lignin, sufite liquor, methyl cellulose, starch and polyvinylpyrrolidone) and lubricants (e.g. Magnesium stearate, talc, stearic acid and sodium lauryl sulfate) mentioned.
  • paraffins e.g. petroleum fractions
  • oils of vegetable origin e.g. peanut or sesame oil
  • monofunctional or polyfunctional alcohols e.
  • the application is carried out in the usual way, preferably by inhalation in the treatment of asthma or COPD.
  • the tablets can of course also contain additives such as sodium citrate, calcium carbonate and dicalcium phosphate together with various additives such as starch, preferably potato starch, gelatin and the like, in addition to the carrier substances mentioned.
  • Lubricants such as magnesium stearate, sodium lauryl sulfate and talc can also be used for tableting.
  • the active ingredients can be mixed with various flavor enhancers or colorants.
  • the dosage of the compounds according to the invention is of course highly dependent on the type of application and the disease to be treated.
  • the compounds of formula 1 When administered by inhalation, the compounds of formula 1 are highly effective even at doses in the ⁇ g range. Even above the ⁇ g range, the compounds of formula 1 can be used expediently. The dosage can then be in the gram range, for example.
  • the finely ground active ingredient, milk sugar and part of the corn starch are mixed together.
  • the mixture is sieved, whereupon it is moistened with a solution of polyvinylpyrrolidone in water, kneaded, wet-granulated and dried.
  • the granules, the rest of the corn starch and the magnesium stearate are sieved and mixed together.
  • the mixture is compressed into tablets of a suitable shape and size.
  • the finely ground active ingredient, part of the corn starch, milk sugar, microcrystalline cellulose and polyvinylpyrrolidone are mixed together, the mixture is sieved and processed with the rest of the corn starch and water to form a granulate which is dried and sieved.
  • the sodium carboxymethyl starch and the magnesium stearate are added, and the mixture is mixed and compressed into tablets of a suitable size.
  • the active ingredient is dissolved in water at its own pH or, if appropriate, at pH 5.5 to 6.5, and sodium chloride is added as an isotonic agent.
  • the solution obtained is filtered pyrogen-free and the filtrate is filled into ampoules under aseptic conditions, which are then sterilized and sealed.
  • the ampoules contain 5 mg, 25 mg and 50 mg of active ingredient.
  • Sorbitan trioleate 0.1 monofluorotrichloromethane
  • Difluorodichloromethane 2 3 ad 100
  • the suspension is filled into a conventional aerosol container with a metering valve. 50 ⁇ l of suspension are preferably dispensed per actuation. If desired, the active ingredient can also be dosed in higher amounts (for example 0.02% by weight).
  • This solution can be prepared in the usual way.
  • the inhalable powder is prepared in the usual way by mixing the individual components.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne des bêta-mimétiques de formule (1), dans laquelle R1 représente un groupe (a) où R3 représente benzyle éventuellement substitué par méthoxy ; R4 représente hydrogène ; ou R3 et R4 représentent conjointement un pont -CO-CH¿2?-O-, le groupe carbonyle de ce pont étant lié à l'azote ; R?2¿ représente un reste sélectionné parmi (b) et (c) où R5 représente diméthylamino, méthoxy ou butoxy ; X représente azote ou carbone ; R6 représente méthoxyphényle, lorsque X représente azote, ou un noyau phényle annelé également lié à X, lorsque X représente carbone. L'invention concerne également des procédés de production de ces composés ainsi que l'utilisation de ces derniers comme médicament.
EP01929560A 2000-04-27 2001-04-14 Nouveaux beta-mimetiques a action lente, leurs procedes de production et leur utilisation comme medicament Withdrawn EP1305300A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
ECSP003424 ECSP003424A (es) 2000-04-27 2000-04-27 NUEVAS COMPOSICIONES DE MEDICAMENTOS A BASE DE COMPUESTOS ANTICOLINERGICAMENTE ACTIVOS Y ß-MIMETICOS
EC003424 2000-04-27
DE2000151318 DE10051318A1 (de) 2000-10-17 2000-10-17 Neu, langwirksame Betamimetika, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE10051318 2000-10-17
PCT/EP2001/004278 WO2001083462A1 (fr) 2000-04-27 2001-04-14 Nouveaux beta-mimetiques a action lente, leurs procedes de production et leur utilisation comme medicament

Publications (1)

Publication Number Publication Date
EP1305300A1 true EP1305300A1 (fr) 2003-05-02

Family

ID=40317111

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01929560A Withdrawn EP1305300A1 (fr) 2000-04-27 2001-04-14 Nouveaux beta-mimetiques a action lente, leurs procedes de production et leur utilisation comme medicament

Country Status (23)

Country Link
US (2) US20020022625A1 (fr)
EP (1) EP1305300A1 (fr)
JP (1) JP2003533448A (fr)
KR (1) KR20020093083A (fr)
CN (1) CN1426401A (fr)
AR (1) AR035637A1 (fr)
AU (1) AU5629301A (fr)
BG (1) BG107120A (fr)
BR (1) BR0110331A (fr)
CA (1) CA2405745A1 (fr)
CZ (1) CZ20023537A3 (fr)
EA (1) EA200201056A1 (fr)
EE (1) EE200200602A (fr)
HR (1) HRP20020845A2 (fr)
HU (1) HUP0300832A2 (fr)
IL (1) IL152140A0 (fr)
MX (1) MXPA02010179A (fr)
NO (1) NO20025133L (fr)
NZ (1) NZ522677A (fr)
PL (1) PL362868A1 (fr)
SK (1) SK15382002A3 (fr)
WO (1) WO2001083462A1 (fr)
YU (1) YU79502A (fr)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
US20030229058A1 (en) * 2001-11-13 2003-12-11 Moran Edmund J. Aryl aniline beta2 adrenergic receptor agonists
WO2003042160A1 (fr) 2001-11-13 2003-05-22 Theravance, Inc. Agonistes de recepteur d'aryl aniline beta-2 adrenergique
DE10246374A1 (de) * 2002-10-04 2004-04-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Betamimetika mit verlängerter Wirkungsdauer, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
US6951888B2 (en) 2002-10-04 2005-10-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Betamimetics with a prolonged duration of activity, processes for preparing them, and their use as pharmaceutical compositions
DE10253220A1 (de) 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Dihydroxy-Methyl-Phenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
DE10253282A1 (de) * 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung
TW200526547A (en) * 2003-09-22 2005-08-16 Theravance Inc Amino-substituted ethylamino β2 adrenergic receptor agonists
DE10349850C5 (de) 2003-10-25 2011-12-08 Clariant Produkte (Deutschland) Gmbh Kaltfließverbesserer für Brennstofföle pflanzlichen oder tierischen Ursprungs
TW200531692A (en) * 2004-01-12 2005-10-01 Theravance Inc Aryl aniline derivatives as β2 adrenergic receptor agonists
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
DE102004003428A1 (de) 2004-01-23 2005-08-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Beta-2-Agonisten, und deren Verwendung als Arzneimittel
US7405232B2 (en) 2004-02-14 2008-07-29 Boehringer Ingelheim International Gmbh Long acting beta-2 agonists and their use as medicaments
EP1720546B1 (fr) * 2004-02-14 2010-09-01 Boehringer Ingelheim International GmbH Nouveaux beta-2-agonistes a action longue duree et leur utilisation comme medicaments
EP1577306A1 (fr) * 2004-03-17 2005-09-21 Boehringer Ingelheim Pharma GmbH & Co.KG nouveaux dérivés de Benzoxazinone comme béta-mimétiques de longue durée et leur utilisation pour le traitement des maladies des voies respiratoires
US7244728B2 (en) 2004-03-17 2007-07-17 Boehringer Ingelheim International Gmbh Long acting betamimetics for the treatment of respiratory diseases
SI1781298T1 (sl) * 2004-04-22 2012-04-30 Boehringer Ingelheim Int Farmacevtske kombinacije, ki vsebujejo benzoksazine, za zdravljenje respiratornih obolenj
US20050272726A1 (en) * 2004-04-22 2005-12-08 Boehringer Ingelheim International Gmbh Novel medicaments for the treatment of respiratory diseases
DE102004019539A1 (de) * 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von Atemwegserkrankungen
US7307076B2 (en) * 2004-05-13 2007-12-11 Boehringer Ingelheim International Gmbh Beta agonists for the treatment of respiratory diseases
JP2007537187A (ja) * 2004-05-13 2007-12-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器疾患の治療においてβアゴニストとして使用するためのヒドロキシ置換ベンゾ縮合ヘテロ環化合物
EP1595873A1 (fr) * 2004-05-13 2005-11-16 Boehringer Ingelheim Pharma GmbH & Co.KG Dérivés de cycloalkyle pour le traitement des maladies respiratoires
DE102004024453A1 (de) * 2004-05-14 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen
US20050255050A1 (en) * 2004-05-14 2005-11-17 Boehringer Ingelheim International Gmbh Powder formulations for inhalation, comprising enantiomerically pure beta agonists
US20050256115A1 (en) * 2004-05-14 2005-11-17 Boehringer Ingelheim International Gmbh Aerosol formulation for the inhalation of beta-agonists
DE102004024454A1 (de) * 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
DE102004024451A1 (de) * 2004-05-14 2005-12-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierungen für die Inhalation, die Enantiomerenreine Betaagonisten enthalten
US7745621B2 (en) 2004-05-14 2010-06-29 Boehringer Ingelheim International Gmbh Long acting bronchodilators for the treatment of respiratory diseases
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
MXPA06013916A (es) * 2004-06-03 2007-03-07 Theravance Inc Agosnistas del receptor adrenergico beta2 de diamina.
EP1778638A1 (fr) * 2004-07-21 2007-05-02 Theravance, Inc. Agonistes des recepteurs beta2 adrenergiques derives d'ethers de diaryle
WO2006031556A2 (fr) * 2004-09-10 2006-03-23 Theravance. Inc. Composes d'arylaniline a substitution amidine
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
DE102005007654A1 (de) 2005-02-19 2006-08-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
EP1924553A1 (fr) 2005-08-08 2008-05-28 Argenta Discovery Limited Dérivés bicyclo[2.2.]hept-7-ylamine et leurs utilisations
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
CA2619402C (fr) 2005-08-15 2015-02-03 Boehringer Ingelheim International Gmbh Procede de production de betamimetiques
US20070088030A1 (en) 2005-10-10 2007-04-19 Barbara Niklaus-Humke Aerosol formulations for the inhalation of beta-agonists
KR101461263B1 (ko) 2005-10-21 2014-11-17 노파르티스 아게 Ｉｌ-13에 대항한 인간 항체 및 치료적 용도
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
AU2007241343B2 (en) 2006-04-21 2011-09-01 Novartis Ag Purine derivatives for use as adenosin A2A receptor agonists
WO2008017638A1 (fr) * 2006-08-07 2008-02-14 Boehringer Ingelheim International Gmbh Nouveaux agonistes beta énantiomériquement purs, procédés pour leur préparation et leur utilisation comme médicament
JP2010500318A (ja) * 2006-08-07 2010-01-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器疾患の治療用医薬組成物
AU2007342223B2 (en) 2007-01-10 2011-02-24 Irm Llc Compounds and compositions as channel activating protease inhibitors
MX2009008493A (es) 2007-02-09 2009-08-20 Irm Llc Compuestos y composiciones como inhibidores de la proteasa activadora de canal.
PT2155721E (pt) 2007-05-07 2011-05-09 Novartis Ag Compostos org?nicos
NZ585789A (en) 2007-12-10 2012-03-30 Novartis Ag Pyrazine-2-carboxamide derivatives to treat diseases mediated by blockade of the epithelial sodium channel
EA201001129A1 (ru) 2008-01-11 2011-02-28 Новартис Аг Пиримидины в качестве ингибиторов киназы
AU2009256645A1 (en) 2008-06-10 2009-12-17 Novartis Ag Pyrazine derivatives as epithelial sodium channel blockers
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
EP2379507B1 (fr) 2008-12-30 2013-10-16 Pulmagen Therapeutics (Inflammation) Limited Composés de sulfonamide pour le traitement de troubles respiratoires
WO2010150014A1 (fr) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited Glitazones 5r-5–deutérés pour le traitement de maladies respiratoires
MX2012004792A (es) 2009-10-22 2013-02-01 Vertex Pharma Composiciones para el tratamiento de fibrosis quistica y otras enfermedades cronicas.
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
WO2011098746A1 (fr) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Sels d'addition acide cristallins de l'énantiomère (5r) de la pioglitazone
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (fr) 2010-09-09 2012-03-15 Irm Llc Composés et compositions comme inhibiteurs de trk
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
ES2551592T3 (es) 2011-02-25 2015-11-20 Novartis Ag Pirazolo[1,5-a]piridinas como inhibidores de TRK
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
ES2882807T3 (es) 2011-09-16 2021-12-02 Novartis Ag Heterociclil carboxamidas N-sustituidas
WO2013038378A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Dérivés pyridinamides
WO2013038381A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Dérivés d'amide pyridine/pyrazine
US9034879B2 (en) 2011-09-16 2015-05-19 Novartis Ag Heterocyclic compounds for the treatment of CF
WO2013038373A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Dérivés pyrimidinamides
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
EA033571B1 (ru) 2014-04-24 2019-11-06 Novartis Ag Производные пиразина в качестве ингибиторов фосфатидилинозитол 3-киназы
CA2945212A1 (fr) 2014-04-24 2015-10-29 Novartis Ag Derives amines de pyrazine utilisables en tant qu'inhibiteurs de la phosphatidylinositol 3-kinase
BR112016024484A2 (pt) 2014-04-24 2017-08-15 Novartis Ag derivados de aminopiridina como inibidores de fosfatidilinositol 3-quinase
WO2020250116A1 (fr) 2019-06-10 2020-12-17 Novartis Ag Dérivé de pyridine et de pyrazine pour le traitement de la fk, de la bpco et de la bronchiectasie
PE20220346A1 (es) 2019-08-28 2022-03-14 Novartis Ag Derivados de 1,3-fenil heteroarilo sustituidos y su uso en el tratamiento de enfermedades
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US133010A (en) * 1872-11-12 Improvement in car-springs
US115681A (en) * 1871-06-06 Improvement in water-wheels
US648621A (en) * 1899-07-24 1900-05-01 James M Hooper Strait-jacket.
DE2540633A1 (de) * 1975-09-12 1977-04-28 Boehringer Sohn Ingelheim Neue quartaere n-beta-substituierte benzilsaeure-n-alkyl-nortropinester und verfahren zu deren herstellung
DE3211185A1 (de) * 1982-03-26 1983-09-29 Boehringer Ingelheim KG, 6507 Ingelheim Neue quartaere 6,11-dihydro-dibenzo-(b,e)-thiepin-11-n-alkyl- norscopinether und verfahren zu deren herstellung
DE3215493A1 (de) * 1982-04-26 1983-11-03 Boehringer Ingelheim KG, 6507 Ingelheim Neue zwischenprodukte, verfahren zu ihrer herstellung und ihre verwendung
US4460581A (en) * 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
DE3743265A1 (de) * 1987-12-19 1989-06-29 Boehringer Ingelheim Kg Neue ammoniumverbindungen, ihre herstellung und verwendung
US5223614A (en) * 1987-12-19 1993-06-29 Boehringer Ingelheim Gmbh New quaternary ammonium compounds, their preparation and use
DE3815480A1 (de) * 1988-05-06 1989-11-16 Boehringer Ingelheim Kg Synergistische kombinationen und ihre verwendung als therapeutika
FR2648709A1 (fr) * 1989-06-23 1990-12-28 Boehringer Ingelheim France Nouvelle utilisation de derives de 1-phenyl-2-aminoethanol en tant que moyens cicatrisants
US5610163A (en) * 1989-09-16 1997-03-11 Boehringer Ingelheim Gmbh Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
DE4014252A1 (de) * 1990-05-04 1991-11-07 Boehringer Ingelheim Vetmed Enantiomerentrennung von cimaterol, (-)-cimaterol und dessen verwendung als arzneimittel oder als leistungsfoerderer
DE4108393A1 (de) * 1991-03-15 1992-09-17 Boehringer Ingelheim Kg Neue ester bi- und tricyclischer aminoalkohole, ihre herstellung und ihre verwendung in arzneimitteln
US5770738A (en) * 1992-03-05 1998-06-23 Boehringer Ingelheim Kg Esters of bi- and tricyclic amino alcohols, their preparation and their use in pharmaceutical compositions
DE19515625C2 (de) * 1995-04-28 1998-02-19 Boehringer Ingelheim Kg Verfahren zur Herstellung von enantiomerenreinen Tropasäureestern
US6506900B1 (en) * 2001-01-31 2003-01-14 Boehringer Ingelheim Pharma Ag Process for preparing a scopine ester intermediate
US7056916B2 (en) * 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0183462A1 *

Also Published As

Publication number Publication date
BG107120A (bg) 2003-05-30
US20020022625A1 (en) 2002-02-21
HUP0300832A2 (hu) 2003-08-28
KR20020093083A (ko) 2002-12-12
CZ20023537A3 (cs) 2003-02-12
US20050137242A1 (en) 2005-06-23
MXPA02010179A (es) 2003-04-25
WO2001083462A1 (fr) 2001-11-08
HRP20020845A2 (en) 2003-10-31
EA200201056A1 (ru) 2003-04-24
CN1426401A (zh) 2003-06-25
CA2405745A1 (fr) 2001-11-08
IL152140A0 (en) 2003-05-29
AR035637A1 (es) 2004-06-23
SK15382002A3 (sk) 2003-03-04
YU79502A (sh) 2006-05-25
EE200200602A (et) 2004-04-15
PL362868A1 (en) 2004-11-02
JP2003533448A (ja) 2003-11-11
AU5629301A (en) 2001-11-12
NO20025133D0 (no) 2002-10-25
NZ522677A (en) 2004-10-29
NO20025133L (no) 2002-10-25
BR0110331A (pt) 2003-01-07

Similar Documents

Publication Publication Date Title
EP1305300A1 (fr) Nouveaux beta-mimetiques a action lente, leurs procedes de production et leur utilisation comme medicament
DE10246374A1 (de) Neue Betamimetika mit verlängerter Wirkungsdauer, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1599478B1 (fr) Dihydropteridinones, prodede de production et utilisation de ces dernieres comme medicaments
EP1328524B1 (fr) Nouveaux anticholinergiques, leurs procedes de production et leur utilisation en tant que medicaments
WO2004046083A1 (fr) Nouveaux derives de dihydroxymethylphenyle, procedes pour leur preparation, et utilisation desdits derives comme medicament
DE69425334T2 (de) 6-(2-imidazolinylamino) chinoxalin-verbindungen als alpha-2-adrenorezeptoragonisten
DE1643262C3 (de) i-Phenoxy^-hydroxy-S-alklyaminopropane, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE69427591T2 (de) 7-(2-imidazolinylamino)quinolin-verbindungen als alpha-2 adrenorezeptor-agonisten
EP1706389A1 (fr) Derives 3-hydroxymethyl-4-hydroxyphenyle pour le traitement de maladies des voies respiratoires
WO2005077361A1 (fr) Nouveaux beta-2-agonistes a action longue duree et leur utilisation comme medicaments
DE2502993A1 (de) Amine, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
DE69424183T2 (de) 6-(2-imidazolinylamino)chinolin-verbindungen als alpha-2-adrenoceptor-antagonisten
DE10258695A1 (de) Neuer, langwirksamer Beta-agonist, Verfahren zu dessen Herstellung und dessen Verwendung als Arzneimittel
EP0132811A1 (fr) Hydroxyméthyl-4 pyrrolidinones substituées en position 1, procédés pour leur préparation, compositions pharmaceutiques et produits intermédiaires
DE10051318A1 (de) Neu, langwirksame Betamimetika, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP0206155B1 (fr) Composés aromatiques, leur préparation et leur application
EP0000479B1 (fr) 1-Pipérazinyl-4H-s-triazolo (3,4-c)thiéno (2,3-e)1,4-diazépines, procédé pour leur préparation et médicaments les contenant
AT329573B (de) Verfahren zur herstellung von neuen thienodiazepinderivaten und ihren salzen
DE4019782A1 (de) 9-amino-2-phenylbicyclo (3.3.1.) und 9-amino-2-phenylbicyclo (3.3.1.) non-2-ene und diese enthaltende therapeutische mittel
EP0031456A1 (fr) Amino-4 diaryl-2,6 tétrahydrothiopyrannes substitués, leurs sels d'addition acides, procédés pour leur préparation et compositions pharmaceutiques
DE4216942A1 (de) Tetrahydro- und Perhydroisochinolin-Derivate und diese enthaltende therapeutische Mittel
DE4216941A1 (de) Para-substituierte Benzylamine und diese enthaltende therapeutische Mittel
DE4225353A1 (de) Neue Pteridine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
EP1483231A1 (fr) Nouveaux sels d'acide cinnamique, procedes de production et d'utilisation comme medicaments
ZA200208658B (en) Novel, slow-acting betamimetics, a method for their production and their use as medicaments.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20021127

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: LT LV RO SI

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20071031